Back to Search
RAFAT ABONOUR, MD
MD
Hematology (Internal Medicine) Physician
NPI: 1750346755IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
01043602A(IN)
Hematology (Internal Medicine) PhysicianPrimary
Internal Medicine — Hematology
Code: 207RH0000X
01043602(IN)01043602A(IN)
CMS Specialties
PrimaryHEMATOLOGY
Education
OTHER
Class of 1984
Research & Publications (20)
Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells.
PMID 10835681·Nat Med·2000
3-trial
Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma.
PMID 19545290·Br J Haematol·2009
8-other
Adaptation of family caregivers during the acute phase of adult BMT.
PMID 19104493·Bone Marrow Transplant·2009
8-other
Gastrointestinal plasmacytoma presenting as gastrointestinal bleeding.
PMID 18854287·Clin Lymphoma Myeloma·2008
5-case
Antimyeloma effects of a sesquiterpene lactone parthenolide.
PMID 18347184·Clin Cancer Res·2008
8-other
A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.
PMID 18000495·Clin Adv Hematol Oncol·2007
8-other
High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors.
PMID 17652649·N Engl J Med·2007
8-other
Hypersensitivity pneumonitis-like syndrome associated with the use of lenalidomide.
PMID 17494808·Chest·2007
5-case
Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21.
PMID 17227904·Oncologist·2007
3-trial
Weekly bortezomib/methylprednisolone is effective and well tolerated in relapsed multiple myeloma.
PMID 17026824·Clin Lymphoma Myeloma·2006
3-trial
Skin cancer after nonmyeloablative hematopoietic cell transplantation.
PMID 16757973·Bone Marrow Transplant·2006
5-case
A pilot study of dose-intensified procarbazine, CCNU, vincristine for poor prognosis brain tumors utilizing fibronectin-assisted, retroviral-mediated modification of CD34+ peripheral blood cells with O6-methylguanine DNA methyltransferase.
PMID 16645619·Cancer Gene Ther·2006
3-trial
Decreased homing of retrovirally transduced human bone marrow CD34+ cells in the NOD/SCID mouse model.
PMID 16569590·Exp Hematol·2006
7-preclinical
In vivo effects of myeloablative alkylator therapy on survival and differentiation of MGMTP140K-transduced human G-CSF-mobilized peripheral blood cells.
PMID 16426896·Mol Ther·2006
7-preclinical
Augmented high-dose regimen of cyclophosphamide, carmustine, and etoposide with autologous hematopoietic stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphoma.
PMID 16194894·Leuk Lymphoma·2005
3-trial
A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease.
PMID 15931635·Biol Blood Marrow Transplant·2005
3-trial
Modulation of in vitro proliferation kinetics and primitive hematopoietic potential of individual human CD34+CD38-/lo cells in G0.
PMID 15613542·Blood·2005
7-preclinical
Impact of modeled microgravity on migration, differentiation, and cell cycle control of primitive human hematopoietic progenitor cells.
PMID 15308329·Exp Hematol·2004
8-other
Secondary leukemias in refractory germ cell tumor patients undergoing autologous stem-cell transplantation using high-dose etoposide.
PMID 15169802·J Clin Oncol·2004
8-other
A multicenter phase 2 trial of stem cell transplantation for immunoglobulin light-chain amyloidosis (E4A97): an Eastern Cooperative Oncology Group Study.
PMID 15156165·Bone Marrow Transplant·2004
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 3 locations total
- Address
- 550 University Blvd Fl 5
Indianapolis, IN 46202 - Phone
- (317) 944-3733
Quick Facts
- NPI
- 1750346755
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 3
- Locations
- 3
- Years in Practice
- 42
- Publications
- 20
Are you this provider?
Claim Your Profile